New Generation Laxatives.
- Author:
Sung Noh HONG
1
;
Jeong Eun SHIN
;
Kyoung Sup HONG
;
Kee Wook JUNG
;
Tae Hee LEE
;
Bong Eun LEE
;
Sun Young PARK
;
Seong Eun KIM
;
Kyung Sik PARK
;
Suck Chei CHOI
Author Information
- Publication Type:Review
- Keywords: Constipation; Laxatives; Prucalopride; Lubiprostone; Linaclotide
- MeSH: Animals; Bile; Bile Acids and Salts; Chloride Channels; Colon; Constipation; Enterohepatic Circulation; Humans; Intestines; Irritable Bowel Syndrome; Laxatives*; Receptors, Serotonin, 5-HT4; Serotonin; Serotonin 5-HT4 Receptor Agonists; Lubiprostone
- From:Korean Journal of Medicine 2015;88(1):9-14
- CountryRepublic of Korea
- Language:Korean
- Abstract: A significant proportion of chronic constipation patients are dissatisfied with their treatment. Recently, a number of new medications have been introduced for patients refractory to conventional laxatives, such as prucalopride, lubiprostone, linaclotide, and elobixibat. Prucalopride is a novel gastrointestinal prokinetic agent that acts as a 5-hydroxytryptamine type 4 (5-HT4) agonist. Compared with older nonselective 5-HT4 agonists, the higher selectivity of prucalopride for 5-HT4 receptors can reduce the risk of significant adverse cardiovascular events. Prucalopride improves stool frequency and consistency, and reduces the need for rescue medications. Lubiprostone, a chloride channel activator, increases the secretion of intestinal fluid, improves the stool frequency and consistency, and reduces straining. Linaclotide, a guanylate cyclase-C agonist, is effective in treating patients with chronic constipation and its effect on visceral sensitivity, as shown mainly in animal studies, provides an attractive pharmaceutical option for patients with irritable bowel syndrome with constipation. Elobixibat is an ileal sodium-dependent bile acid transporter inhibitor that blocks the enterohepatic circulation of bile acids, increasing the bile acid concentration in the intestine, which accelerates colonic transit and softens the stool. A phase III trial of the treatment of chronic constipation and irritable bowel syndrome with constipation is underway. The clinical application of new-generation laxatives will contribute to the management of chronic constipation refractory to conventional laxatives.
